Top Banner Top Banner

Clinical Trials
Ongoing Clinical Trials
Recruiting
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: cisplatin, Drug: docetaxel, Drug: gemcitabine hydrochloride, Drug: pemetrexed disodium, Drug: vinorelbine tartrate
Phase: Phase III
Recruiting
Recruiting
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Pemetrexed, Drug: Paclitaxel, Drug: Carboplatin, Biological: Bevacizumab, Biological: Bevacizumab
Phase: Phase III
Recruiting
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Biological: cetuximab, Drug: carboplatin, Drug: paclitaxel
Phase: Phase III
Recruiting
Study of Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Carboplatin, Drug: Paclitaxel, Biological: Bevacizumab
Phase: Phase III
Recruiting
Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer
Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: Bevacizumab + Pemetrexed, Drug: Bevacizumab + Pemetrexed + Carboplatin
Phase: Phase III
Recruiting
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: pemetrexed disodium
Phase: Phase III
Recruiting
A Study in Second Line Non Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel, Biological: Ramucirumab, Drug: Placebo
Phase: Phase III
Recruiting
ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Conditions: Non Squamous, Non-small-cell Lung Cancer
Interventions: Drug: Tivantinib (ARQ 197) plus erlotinib, Drug: ARQ 197 placebo plus erlotinib
Phase: Phase III
Recruiting
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: Standard of care treatment
Phase: Phase III
Recruiting
A Study of Avastin (Bevacizumab) Versus Placebo in Combination With Carboplatin/Paclitaxel) in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: placebo, Drug: carboplatin, Drug: paclitaxel
Phase: Phase III
Recruiting
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: ARQ 197 and Erlotinib, Drug: Placebo and Erlotinib
Phase: Phase III
Recruiting
Recruiting
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: KD019, Drug: Erlotinib
Phase: Phase III
Recruiting
Erlotinib and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: erlotinib hydrochloride
Phase: Phase II
Recruiting
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer
Interventions: Drug: Cisplatin, Drug: Etoposide, Drug: Placebo, Drug: Cisplatin, Drug: Etoposide, Drug: ZD6474
Phase: Phase II
Recruiting
Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Biological: Avastin
Phase: Phase II
Recruiting
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Drug: pemetrexed disodium, Drug: sunitinib malate
Phase: Phase II
Recruiting
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
Conditions: Locally Advanced Non-Small Cell Lung Cancer, NSCLC
Interventions: Drug: Paclitaxel, Carboplatin and Bevacizumab,Erlotinib
Phase: Phase II
Recruiting
Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: Docetaxel, Drug: Bevacizumab
Phase: Phase II
Recruiting
Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Bevacizumab
Phase: Phase II
Recruiting
Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Carboplatin, Drug: Bevacizumab, Drug: Paclitaxel
Phase: Phase II
Recruiting
Recruiting
Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer
Interventions: Drug: Docetaxel, Drug: Bevacizumab
Phase: Phase II
Recruiting
Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Vinorelbine, Drug: Bevacizumab
Phase: Phase II
Recruiting
Adjuvant Pazopanib in Stage I NSCLC
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PAZOPANIB, Drug: Placebo
Phase: Phase II, Phase III
Recruiting
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: aflibercept, Drug: topotecan hydrochloride
Phase: Phase II
Recruiting
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Conditions: Non-Small Cell Lung Cancer
Interventions: Biological: Imprime PGG® Injection, Biological: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin
Phase: Phase II
Recruiting
Trial of Poor Performance Status Patients (ToPPS)
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Drug: Bevacizumab, Drug: Carboplatin
Phase: Phase II
Recruiting
A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Conditions: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3, Drug: Paclitaxel, Drug: carboplatin
Phase: Phase II
Recruiting
Bevacizumab in Extensive Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer
Interventions: Drug: Standard Chemotherapy (PCDE or PE), Drug: Experimental Treatment (PCDE or PE + bevacizumab), Drug: Prerandomization Chemotherapy (PCDE or PE)
Phase: Phase II, Phase III
Recruiting
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
Conditions: Advanced Non-small Cell Lung Cancer, Postmenopausal Women
Interventions: Drug: fulvestrant (Faslodex), Drug: anastrozole (Arimidex), Drug: Bevacizumab (Avastin), Drug: Best standard of care
Phase: Phase II
Recruiting
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Conditions: Solid Tumors, Cancer
Interventions: Drug: XL184, Drug: Placebo, Drug: XL184, Drug: XL184
Phase: Phase II
Recruiting
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Biological: cixutumumab, Drug: carboplatin, Drug: paclitaxel
Phase: Phase II
Recruiting
NGR-hTNF Administered in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: NGR-hTNF, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed
Phase: Phase II
Recruiting
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed, Cisplatin, Bevacizumab
Phase: Phase II
Recruiting
Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: Suramin + Docetaxel + Carboplatin, Drug: Placebo + Docetaxel + Carboplatin
Phase: Phase II
Recruiting
Molecular Imaging With Erlotinib and Bevacizumab
Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Erlotinib, Bevacizumab, Drug: Fluoro-D-glucose, Drug: Fluoro-L-thymidine, Drug: Gadolinium-DPTA
Phase: Phase II
Recruiting
GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Pazopanib (GW786034)
Phase: Phase II
Recruiting
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: ixabepilone, Drug: bevacizumab
Phase: Phase II
Recruiting
A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: gemcitabine, Drug: gemcitabine, Drug: cisplatin
Phase: Phase II
Recruiting
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
Conditions: Advanced Non-small Cell Lung Cancer
Interventions: Drug: CS-7017, Drug: erlotinib
Phase: Phase II
Recruiting
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: cisplatin, Drug: erlotinib hydrochloride, Drug: pemetrexed disodium, Genetic: gene expression analysis, Genetic: mutation analysis, Other: laboratory biomarker analysis, Other: pharmacogenomic studies
Phase: Phase II
Recruiting
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy
Conditions: Non-small-cell Lung Cancer
Interventions: Drug: AUY922
Phase: Phase II
Recruiting
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: imetelstat, Drug: Bevacizumab
Phase: Phase II
Recruiting
Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
Conditions: Small Cell Lung Cancer
Interventions: Drug: Sorafenib
Phase: Phase II
Recruiting
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab), Drug: Pemetrexed, Drug: Carboplatin (AUC 6), Drug: Cisplatin, Drug: Gemcitabine, Drug: Carboplatin (AUC 5)
Phase: Phase II
Recruiting
Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: carboplatin paclitaxel bevacizumab, Drug: Standard treatment plus nitroglycerin
Phase: Phase II
Recruiting
Stage IIIB/IV Non-Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: Pazopanib plus Paclitaxel
Phase: Phase II
Recruiting
RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy
Conditions: Lung Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097, Genetic: fluorescence in situ hybridization, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Other: pharmacogenomic studies, Other: pharmacological study
Phase: Phase II
Recruiting
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy
Conditions: Lung Cancer
Interventions: Drug: pazopanib hydrochloride, Other: laboratory biomarker analysis, Other: pharmacogenomic studies, Other: pharmacological study, Procedure: quality-of-life assessment
Phase: Phase II, Phase III
Recruiting
Recruiting
Selumetinib and Erlotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Drug: erlotinib hydrochloride, Drug: selumetinib
Phase: Phase II
Recruiting
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study
Conditions: Lung Cancer
Interventions: Drug: Erlotinib, Drug: AZD6244, Drug: MK-2206, Drug: Sorafenib, Drug: Erlotinib, Drug: MK-2206
Phase: Phase II
Recruiting
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Conditions: Lung Cancer
Interventions: Drug: Pazopanib
Phase: Phase II
Recruiting
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
Conditions: Lung Cancer
Interventions: Drug: Carboplatin, Drug: Pemetrexed, Drug: Bevacizumab, Drug: Cetuximab, Drug: Cixutumumab
Phase: Phase II
Recruiting
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Conditions: Lung Cancer
Interventions: Drug: Akt inhibitor MK2206, Drug: erlotinib hydrochloride, Other: laboratory biomarker analysis, Other: pharmacological study
Phase: Phase II
Recruiting
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel, Drug: BKM120 or Docetaxel or Pemetrexed
Phase: Phase II
Recruiting
Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: SB injection
Phase: Phase II
Recruiting
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
Interventions: Drug: AZD, Drug: MK-2206, Drug: Lapatinib, Drug: Erlotinib, Drug: Sunitinib, Procedure: Molecular Profiling
Phase: Phase II
Recruiting
Recruiting
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
Conditions: Carcinoma, Large Cell, Neuroendocrine Tumors
Interventions: Drug: RAD001 + paclitaxel/carboplatin
Phase: Phase II
Recruiting
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers
Conditions: Lung Cancer
Interventions: Biological: bevacizumab, Drug: carboplatin, Drug: erlotinib hydrochloride, Drug: pemetrexed disodium
Phase: Phase II
Recruiting
Recruiting
Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)
Conditions: NSCLC
Interventions: Drug: Bevacizumab, Drug: Cisplatin, Drug: Docetaxel
Phase: Phase II
Recruiting
Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: ARQ 197 plus erlotinib, Drug: Pemetrexed, docetaxel or gemcitabine
Phase: Phase II
Recruiting
A Study of Axitinib in Advanced Carcinoid Tumors
Conditions: Carcinoid Tumor
Interventions: Drug: Axitinib
Phase: Phase II
Recruiting
Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941, Drug: carboplatin, Drug: paclitaxel, Drug: bevacizumab, Drug: Placebo
Phase: Phase II
Recruiting
Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer
Interventions: Drug: pegylated endostatin and Paclitaxel-Carboplatin, Drug: Placebo and Paclitaxel-Carboplatin
Phase: Phase II
Not yet recruiting
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
Conditions: Small Cell Lung Cancer, Small Cell Lung Cancer Recurrent
Interventions: Drug: BIBF 1120
Phase: Phase II
Not yet recruiting
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258, Drug: bevacizumab [Avastin], Drug: pemetrexed, Drug: Placebo, Drug: cisplatin/carboplatin, Drug: paclitaxel
Phase: Phase II
Not yet recruiting
BKM120 in Cancers With PIK3CA Activating Mutations
Conditions: Lung Cancer, Breast Cancer, Colorectal Cancer, Cholangiocarcinoma, Solid Tumors
Interventions: Drug: BKM120
Phase: Phase II
Not yet recruiting
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab, Drug: Placebo, Drug: paclitaxel, Drug: cisplatin/carboplatin
Phase: Phase II
Not yet recruiting
Not yet recruiting
Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations
Conditions: Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib, Biological: bevacizumab, Other: laboratory biomarker analysis
Phase: Phase II


Clinical Trial Data provided by http://www.clinicaltrials.gov.




Last updated February 29, 2012